The Type IV phosphodiesterase inhibitor rolipram induces expression of the cell cycle inhibitors p21Cip1and p27Kip1, resulting in growth inhibition, increased differentiation, and subsequent apoptosis of malignant A-172 glioma cells

Cancer Biology and Therapy

Volumn 1, Issue 3, 2002, Pages 268-276

  Chen, Thomas C ^a,b   Wadsten, Pia ^c,d   Su, Susan ^a   Rawlinson, Neal ^c   Hofman, Florence M ^b   Hill, Colin K ^b   Schönthal, Axel H ^c  

^a LAC USC MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d LINNAEUS UNIVERSITY   (Sweden)

Author keywords

cAMP; Cell cycle; Glioma; Phosphodiesterase inhibitor; Rolipram

Indexed keywords

3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CDKN1A PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLINE; DNA; ENZYME INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; ROLIPRAM; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; ARTICLE; CANCER INVASION; CELL CULTURE; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; DNA RESPONSIVE ELEMENT; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVATION; GENETIC TRANSFECTION; GLIOMA; HUMAN; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROMOTER REGION; WESTERN BLOTTING;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE PROTEINS; CELL DIFFERENTIATION; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLINS; DNA, NEOPLASM; ENZYME ACTIVATION; ENZYME INHIBITORS; G1 PHASE; GLIOMA; HUMANS; NEOPLASM INVASIVENESS; PHOSPHODIESTERASE INHIBITORS; PROMOTER REGIONS (GENETICS); RESPONSE ELEMENTS; ROLIPRAM; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 1842847981     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.80     Document Type: Article

References (54)

1. Giles GG, Gonzales MF. Epidemiology of brain tumors and factors in prognosis. In: Kaye AH, Laws ER, eds. Brain Tumors, Edinburgh, Scotland: Churchill Livingstone, 1995:47-69.
2. Chang SM, Prados MD. Chemotherapy for gliomas. Curr Opin Oncol 1995; 7:207-13.
3. Couldwell WT, Hinton DR, He S, Chen TC, Sebat I, Weiss MH, et al. Protein kinase C inhibitors induce apoptosis in human malignant glioma cell lines. FEBS Letters 1994; 345:43-6. (Pubitemid 24154662)
4. Pollack IF, Randall MS, Kristofik MP, Kelly RH, Selker RG, Vertosick FT. Response of malignant glioma cell lines to activation and inhibition of human malignant glioma cell lines in vitro. Cancer Res 1990; 50:7134-8.
5. Couldwell WT, Hinton DR, Surnock AA, DeGiorgio CM, Weiner LP, Apuzzo MLJ, et al. Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clin Cancer Res 1996; 2:619-22.
6. Couldwell WT, Gopalkrishna R, Hinton D, He S, Weiss MH, Apuzzo MLJ, et al. Hypericin: a potential antiglioma therapy. Neurosurgery 1994; 35:705-10. (Pubitemid 24299905)
7. Furman MA, Shuman K. Cyclic AMP and adenyl cyclase in brain tumors. J Neurosurg 1977; 46:477-83.
8. Racagni G, Pezzotta S, Giordana MT, Iuliano E, Mocchetti I, Giaovanni S, et al. Cyclic nucleotides in experimental and human brain tumors. J Neuro-Oncol 1983; 1:61-7. (Pubitemid 13087850)
9. Cho-Chung YS, Clair T. The regulatory subunit of cAMP-dependent protein kinase as a target for chemotherapy of cancer and other cellular dysfunctional-related diseases. Pharmac Ther 1993; 60:265-88. (Pubitemid 24117379)
10. Rohlff C, Clair T, Cho-chung YS. 8-Cl-cAMP induces truncation and down-regulation of the RIa subunit and up-regulation of the RIIB subunit of cAMP-dependent protein kinase leading to type II holoenzyme-dependent growth inhibition and differentiation of HL-60 leukemia cells. J Biol Chem 1993; 268:5774-82. (Pubitemid 23090906)
11. Tsai CH, Hung LM, Cheng HP, Chen JK. Increased intracellular cyclic AMP levels suppress the mitogenic responses of human astrocytoma cells to growth factors. J Neuro-Oncol 1995; 23:41-52.
12. Chen TC, Hinton DR, Zidovetzki R, Hofman FM. Up-Regulation of the cAMP/PKA pathway inhibits proliferation, induces differentiation, and leads to apoptosis in malignant gliomas. Lab Inv 1998;165-74. (Pubitemid 28113455)
13. Conti M, Nemoz G, Sette C, Vicini E. Recent progress in understanding the hormonal regulation of phosphodiesterases. Endocrine Reviews 1995; 16:370-89.
14. Zhu W, Majluf-Cruz A, Omburo GA. Cyclic AMP-specific phosphodiesterase inhibitor rolipram and RO-20-1724 promoted apoptosis in HL60 promyelocytic leukemic cells via cyclic AMP-independent mechanism. Life Sci 1998; 63:265-74. (Pubitemid 28302469)
15. Scott AIF, Perini AF, Shering PA, Whalley LJ. In-patient major depression: is rolipram as effective as amitriptyline? Eur J Clin Pharmacol 1991; 40:127-9.
16. Sommer N, Loschmann PA, Northoff GH, Weller M, Steinbrecher A, Steinbach JP, et al. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nature Med 1995; 1:244-8.
17. McLaughlin MM, Cieslinski LB, Burman M, Torphy TJ, Livi GP. A low-Km, rolipram-sensitive, cAMP-specific phosphodiesterase from human brain. J Biol Chem 1993; 268:6470-6476.
18. Krause W, Kuhne G, Matthes H. Pharmacokinetics of the antidepressant rolipram in healthy volunteers. Xenobiotica 1989; 19:683-92. (Pubitemid 19147787)
19. Krause W, Kuhne G, Jakobs U, Hoyer GA. Biotransformation of the antidepressant DL-Rolipram. I. Isolation and identification of metabolites from rat, monkey, and human urine. Drug Metab Dispos 1993; 29:682-9.
20. Hebenstreit GF, Fellerer K, Fichte K, Fischer G, Geyer N, Meya U, et al. Rolipram in major depressive disorder: Results of a double-blind comparative study with imipramine. Pharmacopsychiat 1989; 22:156-60.
21. Harlow E, Lane D: Antibodies: A Laboratory Manual. Cold Spring Harbor: Cold Spring Harbor Laboratory, 1988
22. Schonthal A, Sugarman J, Brown JH, et al: Regulation of c-fos and c-jun protooncogene expression by the Ca(2+)- ATPase inhibitor thapsigargin. Proc Natl Acad Sci USA 1991; 88:7096-100.
23. Southern PJ, Berg P: Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter. J Mol Appl Genet 1982; 1:327-41. (Pubitemid 12056513)
24. El-Deiry WS, Tokino T, Waldman T, et al: Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res 1995; 55:2910-19.
25. Wu R-C, Schönthal AH: Activation of p53-p21waf1 pathway in response to disruption of cell-matrix interactions. J Biol Chem 1997; 272:29091-8. (Pubitemid 27498197)
26. Ausubel FM, Brent R, Kingston RE. Current Protocols in Molecular Biology. Chanda VB, ed. John Wiley & Sons, Inc., 1994.
27. Schonthal A, Alberts AS, Frost JA, Feramisco JR. Differential regulation of jun family gene expression by the tumor promoter okadaic acid. New Biol 1991; 3:977-86.
28. Graña X, Reddy EP. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDK's), growth suppressor genes and cyclin-dependent kinase inhibitors (CKI's). Oncogene 1995; 11:211-19.
29. Roger PP, Reuse S, Maenhaut C, Dumont J E. Multiple facets of the modulation of growth by cAMP. Vitam Horm 1995; 51:59-191.
30. Propper DJ, Saunders MP, Salisbury AJ, Long L, O'Byrne KJ, Braybrooke JP, et al. Phase I study of the novel cyclic AMP (cAMP) analogue 8-Chloro-cAMP in patients with cancer: toxicity, hormonal, and immunological effects. Clin Cancer Res 1999; 5:1682-9.
31. Denis D, Riendeau D. Phosphodiesterase 4-dependent regulation of cyclic AMP levels and leukotriene B4 biosynthesis in human polymorphonuclear leukocytes. Eur J Pharmacol 1999; 367:343-50. (Pubitemid 29106388)
32. Morgan AJ, Murray KJ, Challiss RAJ. Comparison of the effect of isobutylmethylxanthine and phosphodiesterase-selective inhibitors on cAMP levels in SH-SY5Y neuroblastoma cells. Biochem Pharmacol 1993; 2373-2380. (Pubitemid 23189528)
33. Fleischhacker WW, Hinterhuber H, Bauer H, Pflug B, Berner P, Simhandl C, et al. A multicenter double-blind study of patients with major depressive disorder. Neuropsychobio 1992; 26:59-64.
34. Yamashita N, Yamauchi M, Baba J, Sawa A. Phosphodiesterase type 4 that regulates cAMP level in cortical neurons shows high sensitivity to rolipram. Eur J Pharmacol 1997; 337:95-102. (Pubitemid 27468866)
35. Belayev L, Busto R, Ikeda M, Rubin LL, Kajiwara A, Morgan L, et al. Protection against blood-brain barrier disruption in focal cerebral ischemia by the type IV phosphodiesterase inhibitor BBB022: a quantitative study. Brain Res 1998; 787:277-85. (Pubitemid 28197915)
36. Mayer B, Montminy M. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol 2001; 2:599-609. (Pubitemid 33674011)
37. Frisch S M. cAMP takes control. Nat Cell Biol 2000; 2:E167-8.
38. Banner KH, Hoult JR, Taylor MN, Landells LJ, Page CP. Possible contribution of Prostaglandin E2 to the antiproliferative effect of phosphodiesterase 4 inhibitors in human mononuclear cells. Biochem Pharmacol 1999; 58:1487-95. (Pubitemid 29438650)
39. Horn VJ, Baum BJ, Ambudkar IS. Beta-adrenergic receptor stimulation induces inositol trisphosphate production and Ca2+ mobilization in rat parotid acinar cells. J Biol Chem 1988; 263:12454-60. (Pubitemid 19000426)
40. Doucas V, Shi Y, Miyamoto S, West A, Verma I, Evans RM. Cytoplasmic catalytic subunit of protein kinase A mediates cross- repression by NF-kappa B and the glucocorticoid receptor. Proc Natl Acad Sci USA 2000; 97:11893-8.
41. Zurbonsen K, Michel A, Vittet D, Bonnet PA, Chevillard C. Dissociation between phosphodiesterase inhibition and antiproliferative effects of phosphodiesterase inhibitors on the Dami cell line. Biochem Pharmacol 1997; 53:1141-7. (Pubitemid 27224260)
42. Gomez-Manzano C, Fueyo J, Kyritsis AP, McDonnell TJ, Steck PA, Levin VA, et al. Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis, J Natl Cancer Inst 1997; 89:1036-44. (Pubitemid 27327868)
43. Chen J, Willingham T, Shuford M, Bruce D, Rushing E, Smith Y, et al. Effects of ectopic overexpression of p21(WAF1/CIP1) on aneuploidy and the malignant phenotype of human brain tumor cells. Oncogene 1996; 13:1395-40.
44. Chen J, Willingham T, Shuford M, Nisen PD. Tumor suppression and inhibition of aneuploid cell accumulation in human brain tumor cells by ectopic overexpression of the cyclin-dependent kinase inhibitor p27Kip1. J Clin Invest 1996; 97:1983-8.
45. Gomez-Manzano C, Fueyo J, Kyritsis AP, Steck PA, Roth JA, McDonnell TJ, et al. Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res 1996; 56:694-9. (Pubitemid 26055454)
46. Bates S, Vousden KH. p53 in signaling checkpoint arrest or apoptosis. Curr Opin Genetics Devel 1996; 6:12-19. (Pubitemid 2614897)
47. Iwadate Y, Fujimoto S, Tagawa M, Namba H, Sueyoshi K, Hirose M, et al. Association of p53 gene mutation with decreased chemosensitivity in human malignant gliomas. Int J Cancer 1996; 69:236-40. (Pubitemid 26233304)
48. Lang FF, Yung WKA, Raju U, Libuna F, Terry NH, Tofilon PJ, et al. Enhancement of radiosensitivity of wild-type p53 human glioma cells by adenovirus-mediated delivery of the p53 gene. J Neurosurg 1998; 89:125-32. (Pubitemid 28285933)
49. Nieder C, Petersen S, Petersen C, Thames HD. The challenge of p53 as prognostic and predictive factor in gliomas. Cancer Treat Rev 2000; 26:67-73. (Pubitemid 30102801)
50. Haynes LW, Weller RO. Induction of some features of glial differentiation in primary cultures of human gliomas by treatment with dibutyrl cyclic AMP. Br J Exp Pathol 1978; 59:259-76. (Pubitemid 9000300)
51. Drabek K, Pesic M, Piperski V, Ruzdijic S, Medic-Mijacevic L, Pietrzkowski Z, et al. 8-Cl-cAMP and tiazofurin affect vascular endothelial growth factor production and glial fibrillary acidic protein expression in human glioblastoma cells. Anticancer Drugs 2000; 11:765-70.
52. Ohsawa F, Yamauchi M, Nagaso H, Murakami S, Baba J, Sawa A. Inhibitory effects of rolipram on partially purified phosphodiesterase 4 from rat brains. Jpn J Pharmacol 1998; 77:147-54. (Pubitemid 28336347)
53. Merz KH, Marko D, Regiert T, Reiss G, Frank W, Eisenbrand G. Synthesis of 7-benzylamino-6-chloro-2-piperazino-4-pyrrolidinopteridine and novel derivatives free of positional isomers. Potent inhibitors of cAMP-specific phosphodiesterase and of malignant tumor cell growth. J Med Chem 1998; 41:4733-43. (Pubitemid 28530450)
54. Chen TC, Weiss MH, Hofman FM. Synergistic inhibition of malignant gliomas with rolipram and hypericin: combination therapy with modulation of the cAMP/PKA and PKC pathways. Abstract. Congress of Neurological Surgeons, 10-98, Seattle, Washington.